18 results about "Synovial fluid" patented technology

The present invention relates to a hydrogel composition for intra-articular administration, which is easily injected into the human body, and use thereof for supplementing joint synovial fluid, supplementing viscosity, and preventing or treating intra-articular lesions. The hydrogel composition according to the present invention can improve the gelation temperature, viscosity, biodegradability, and tissue support capability of hyaluronic acid and, at the same time, can improve practitioner convenience and patient compliance due to the reduced injection pressure thereof. In addition, the hydrogel composition can increase the effect of ameliorating intra-articular lesions when co-administered with stem cells or exosomes, and thus can have various applications in medical devices and pharmaceutical fields for the purpose of cartilage regeneration and intra-articular lesion treatment.

Disclosed are methods for detecting extracapsular synovial fluid or components thereof as a marker for initiation of processes that lead to degenerative joint disease in a subject.

To provide a method for restoring the synovial surface properties of a synovial surface film that has been damaged and whose synovial surface properties have deteriorated. [Solution] A method for restoring the synovial surface properties of a synovial surface film, comprising a standing step of allowing the damaged synovial surface film, whose synovial surface properties have deteriorated, to stand for more than 5 minutes, wherein the synovial surface film is a synovial surface film containing a liquid organic compound at 25°C and 1 atm.

The present application relates to the technical field of genetic testing, and discloses a sample diluent, a sample preparation method, and a rheumatoid arthritis test kit. The sample diluent comprises the following concentrations of components: 5-40 g / L of an alkali metal salt, 1-20 g / L of a protein protectant, 5-50 mM of an alkyl glycoside surfactant, 0.01-0.1% of a Tween surfactant, 1-100 μg / mL of an immunoadsorbent, and 10-200 mM of a buffer, wherein the pH value of the buffer ranges from 6.5 to 8.0. The present application provides an actual basis for synovial fluid testing in clinical rheumatoid arthritis, and takes into account a small sample size, such as testing of a site where synovial fluid is difficult to aspirate. In addition, by using an iFlash series instrument, a result can be obtained in as little as 10 min. Compared with the operating time of at least 1 hour of conventional ELISA, the test process is greatly accelerated, and high sensitivity and specificity are achieved.

This invention provides an exercise assistance device that assists the user in moving their hip joint in multiple directions, thereby improving the effects of increased synovial fluid, stretching, and muscle training. [Solution] The exercise assist device comprises a base that is placed on the floor, a seat on which the user sits, and legs connecting the base and the seat, the legs having at least one of a first connecting portion that rotatably connects the lower end to the base and a second connecting portion that rotatably connects the upper end to the seat.

The invention discloses a detection kit for detecting the content of calprotectin in synovial fluid. The detection kit comprises a detection kit shell and a calprotectin immunochromatography test strip, and the calprotectin immunochromatography test strip is arranged in the detection kit shell; the calprotectin immunochromatography test strip comprises a sample pad, a glass fiber combination pad, a coated nitrocellulose membrane and a water absorption pad which are bonded in sequence, an anti-calprotectin antibody marked by colloidal gold is embedded in the glass fiber combination pad and is used for being combined with calprotectin in a sample to be detected to form a compound; the anti-calprotectin monoclonal antibody is coated on a detection line of the nitrocellulose membrane, and the anti-mouse IgG antibody is coated on a quality control line of the nitrocellulose membrane; the colloidal gold labeled anti-calprotectin antibody is embedded in the glass fiber cushion layer, and the image recognition module is used for collecting a tested test paper image and calculating a relative gray value of a detection line and a quality control line, so that a calprotectin concentration interval is judged.

The invention provides a 3D synovial cartilage organ chip with a bionic structure and a preparation method and application thereof, and relates to the technical field of organ chip manufacturing. The organ chip comprises a main body; the main body comprises a top layer, a cartilage layer, a joint synovial fluid layer, a synovial membrane and an endothelial channel layer which are arranged in sequence; a cartilage cavity for accommodating articular cartilage cells is formed in the cartilage layer; a synovial fluid cavity used for containing joint synovial fluid is formed in the joint synovial fluid layer. A synovial membrane channel and an immune cell channel are arranged in the synovial membrane and endothelial channel layer in parallel; a permeation zone is arranged between the synovial membrane channel and the immune cell channel; a pressure cavity is formed in the top layer, and an elastic film is arranged on the portion, on one side of the cartilage cavity, of the pressure cavity. According to the scheme, mechanical stimulation is integrated into the organ chip, and in-vivo periodic compression during walking / activity of a human body can be reproduced, so that mechanical-biochemical coupling of a cartilage-synovial membrane-bone interface is simulated more truly, and the similarity of an in-vitro model is improved.

A surgical system includes a surgical generator and at least one energy delivery device. The surgical generator includes at least one energy output stage configured to deliver energy, a controller configured to control the energy output, and sensor circuitry. The energy delivery device(s) is coupled to the surgical generator, configured for insertion into a synovial joint, and configured to supply energy through synovial fluid in the synovial joint. In a sensing mode, the sensor circuitry is configured to sense at least one electrical parameter of the energy and the controller is configured to determine a parameter of the synovial fluid based thereon. The controller is further configured, in a treatment mode, to control the energy based upon the at least one determined parameter of the synovial fluid to treat tissue of the synovial joint.

The present disclosure is directed to a kit and methods for using the same. The kit includes a plate including at least one well, wherein the well includes a silver nitrate and a catalyst. The method includes providing a sample of synovial fluid to a well of a plate, wherein the well includes a silver nitrate and a catalyst and determining a presence of monosodium urate (MSU) crystals, wherein the presence of MSU crystals indicates that gout is detected in the sample.

The invention discloses a protein sample pretreatment kit and a proteome sample pretreatment method, the protein sample pretreatment kit comprises a reduction alkylation reagent, a protein extraction agent, a desalting reagent and an extractor, the amount of filler in the extractor is 0.8-1.5 mg, the amount of fixed polypeptide is 15-25 [mu] g, the amount of the protein extraction agent in the extractor is 0.5-1.5 mg, the amount of the protein extraction agent in the extractor is 0.5-1.5 mg, the amount of the protein extraction agent in the extractor is 0.5-1.5 mg, and the amount of the protein extraction agent in the extractor is 0.5-1.5 mg. During use, saliva, blood, cerebrospinal fluid, synovial fluid, clinical tissue samples, IP magnetic bead samples or electrophoretic band samples can be treated, the pretreatment difficulty is greatly reduced, the sample pretreatment difficulty is reduced, operation by non-professionals is facilitated, sample pretreatment becomes a standardized process, the process controllability and stability are remarkably improved, the reproducibility is improved along with improvement, and the method is suitable for popularization and application. Various types of samples can be treated, and clinical samples, IP magnetic bead samples, electrophoretic band samples and the like can be treated respectively.

The invention discloses application of a synovial fluid source exosome miRNA marker in an osteoarthritis diagnosis product, and belongs to the field of biological medicine detection. The synovial fluid source exosome miRNA marker is miR-3196, and the reagents comprise reagents for detecting the expression level of the synovial fluid source exosome miRNA marker miR-3196 by a sequencing technology, a nucleic acid hybridization technology and a nucleic acid amplification technology. Experimental verification finds that miR-3196 is remarkably low in expression in a synovial fluid exosome of an OA patient, after the miR-3196 low in expression in the exosome is taken by cartilage cells, related signal channels are activated and degradation of the cartilage cells is promoted by regulating MAPK15 in the cartilage cells in a targeted mode, and the miR-3196 can be applied to early clinical diagnosis of osteoarthritis.

Compositions, methods, and kits are provided for diagnosing bacterial infections that distinguish tissue infected with dormant bacteria from uninfected tissue. In particular, the subject methods can be used to detect dormant bacteria, including bacteria in biofilms on joint replacement implants by measuring biomarkers in synovial fluid or blood or analyzing specific immune cell types, including regulatory T-cells, natural killer cells, monocytes, plasmacytoid dendritic cells, or myeloid dendritic cells within a periarticular tissue sample in contact with the effective joint space of an implant.

This invention relates to the field of lubricant technology, specifically to a diatomaceous earth@phospholipid microcapsule, its preparation method, and its uses. The diatomaceous earth@phospholipid microcapsule is a disc-shaped structure with a particle size of 20-30 micrometers. It is formed by covering the surface of a disc-shaped diatomaceous earth layer with a phospholipid bilayer, and filling the cavities of the disc-shaped diatomaceous earth with phospholipids. The diatomaceous earth@phospholipid microcapsule of this invention can exist relatively stably on the cartilage surface, forming a protective lubricating film. This not only prevents existing cartilage from being worn down, but also further improves the fluidity of synovial fluid, enhances the delivery of nutrients in the synovial fluid, and promotes the metabolic activity of chondrocytes, thereby promoting cartilage repair.

Rheumatoid arthritis (RA) is the most common form of inflammatory rheumatism involving small joints which are the seat for swelling and pain with structural damage, responsible for functional disabilities if no treatment is proposed. The inventors show that circulating MAIT cells were reduced and exhibited an activated and anti-apoptotic phenotype in RA patients compared to healthy controls. MAIT cell levels were also found to be increased in the synovial fluid as compared with the peripheral blood, suggesting that circulating MAIT cell deficiency is due to the migration of MAIT cells into the joint. Severity of arthritis induced by mBSA was reduced in mice depleted in MAIT cells. This data suggest that MAIT cells contribute to exacerbation of arthritis. Thus the present invention relates to the use of an agent capable of inhibiting the activation of MAIT cells for the treatment of rheumatoid arthritis

The invention discloses a PJI diagnosis model based on serum and synovial fluid indexes and a construction method of the PJI diagnosis model, and aims to solve the problems that in existing PJI diagnosis, specificity of a single index is insufficient, and misjudgment is easily caused due to culture negative. According to the method, serum and joint fluid samples and clinical information of all-joint replacement postoperative revision patients are collected, multiple types of clinical indexes are extracted after data processing and queue division, and eight core indexes are screened out by adopting LASSO logistic regression in combination with single-factor and multi-factor logistic regression; and constructing a visual column graph model containing a scoring system and a probability transformation formula through an R language. The model fully considers index weight and interaction, has the characteristics of low cost, easy acquisition and accurate diagnosis, is reliable in performance through training and verification queue verification, can assist clinicians in making scientific judgment before invasive treatment and reduce unnecessary detection and medical burden, and is suitable for popularization and application of medical institutions at all levels.

The invention belongs to the field of pet food processing, and relates to a premix for improving joint health of pets and a preparation method thereof. The premix is added with the following natural components: rhizoma polygonati, rhizoma drynariae, eucommia ulmoides, ligusticum wallichii, liquorice, turmeric, poria cocos and Chinese yam. The whole formula has the effects of tonifying liver and kidney to consolidate the root, promoting blood circulation to remove meridian obstruction to treat symptoms, tonifying spleen to remove dampness to assist transportation and transformation, tonifying spleen to prevent dampness stagnation, promoting diuresis to prevent positive qi injury, treating both symptoms and root causes, combining dredging and tonifying, and directly reaching the effects on joints. The premix can tonify cartilage, strengthen ligament, relieve pain, supplement synovial fluid, effectively improve the arthritis health of pets and improve the life quality of pets.

The invention provides a composition containing a plant extract and calcium and application of the composition to bone joint health. The composition can repair cartilage, promote secretion of bone joint lubricating liquid, remove inflammatory cells, inhibit inflammatory factors, delay cartilage degeneration, improve bone mineral density and bone strength, maintain bone mineral density, enhance bone firmness, improve osteoporosis and improve arthritis.

Disclosed herein are methods of treating or preventing rheumatoid arthritis by administering a syndecan-1 inhibitor or a synthenin-1 inhibitor capable of preventing syndecan-1 from binding to the PDZ-2 domain of syntenin-1. Also disclosed herein are methods of reducing or ameliorating one or more symptoms of rheumatoid arthritis, reducing syntenin-1 or syndecan-1 in synovial fluid or blood, reducing synovial inflammation, reducing cartilage degradation, reducing one or more inflammatory interferon transcription factors, reducing one or more monokines, reducing expression of one or more glycolytic factors, or increasing expression of one or more oxidative intermediates or enzymes in a subject.